Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/ gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4year (y) follow-up (FU) of CheckMate 649

被引：0
|
作者：
Wyrwicz, L. S. [1 ]
Shitara, K. [2 ]
Moehler, M. [3 ]
Ajani, J. A. [4 ]
Shen, L. [5 ]
Garrido, M. [6 ]
Gallardo Araneda, C. E. [7 ]
Yamaguchi, K. [8 ]
Cleary, J. [9 ]
Elimova, E. [10 ]
Bruges Maya, R. [11 ]
Karamouzis, M. V. [12 ]
Skoczylas, T. [13 ]
Bragagnoli, A. C. [14 ]
Liu, T. [15 ]
Tehfe, M. [16 ]
Feeney, K. [17 ,18 ]
Wang, R. [19 ]
Zhang, J. [20 ]
Janjigian, Y. Y. [21 ,22 ]
机构：
[1] Narodowy Instytut Onkol, Dept Radiotherapy & Oncol, Klin Onkol & Radioterapii, Warsaw, Poland
[2] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[3] Johannes Gutenberg Univ Clin, Dept Med, Mainz, Germany
[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA
[5] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res Minist Educ, Dept Gastrointestinal Oncol, Beijing, Peoples R China
[6] Pontificia Univ Catolica, Hematooncol Dept, Clin San Carlos de Apoquindo, Santiago, Chile
[7] Fdn Arturo Lopez Perez, Dept Med Oncol, Providencia, Chile
[8] Canc Inst Hosp JFCR, Gastroenterol Chemotherapy Dept, Koto Ku, Tokyo, Japan
[9] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[10] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada
[11] Inst Nacl Cancerol ESE, Oncol Clin, Bogota, Colombia
[12] Laiko Gen Hosp Athens, Dept Biol Chem, Athens, Greece
[13] Med Univ Lublin, Dept Gen Surg, Klin Chirurg Ogolnej Gastroenterologicznej & No 2, Lublin, Poland
[14] Fundacao Pio Xii Hosp Canc Barretos, GI Canc, Barretos, Brazil
[15] Fudan Univ, Zhongshan Hosp, Oncol Dept, Shanghai, Peoples R China
[16] Ctr Hosp Univ Montreal, Oncol Ctr, Hematooncol Dept, Montreal, PQ, Canada
[17] Notre Dame Univ, Dept Canc Serv, Murdoch, WA, Australia
[18] Edith Cowan Univ, Murdoch, WA, Australia
[19] Bristol Myers Squibb, Oncol Precis Med, Princeton, NJ USA
[20] Bristol Myers Squibb, Oncol Clin Dev, Princeton, NJ USA
[21] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[22] Weill Cornell Med Coll, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.333
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
419P
引用
收藏
页码：S169 / S170
页数：2
相关论文
共 50 条
  • [21] Q-TWiST analysis of nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC) in patients with PD-L1 CPS≥1 and CPS≥5: 4-year follow-up from CheckMate 649 (CM 649)
    Lin, D.
    Quan, W.
    Garretson, M.
    Chirikov, V. V.
    Chen, C.
    Singh, P.
    Davis, C.
    Sugarman, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S170 - S170
  • [22] Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC)
    Sugarman, Ryan
    Nunna, Sasikiran
    Betts, Keith A.
    Nie, Xiaoyu
    Nguyen, Hiep
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [23] Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649)
    Lin, Daniel
    Quan, Wenying
    Garretson, Marne
    Chirikov, Viktor
    Chen, Clara
    Singh, Prianka
    Davis, Catherine
    Sugarman, Ryan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Cleary, James M.
    Elimova, Elena
    Karamouzis, Michalis
    Bruges, Ricardo
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshi
    Tehfe, Mustapha
    Zander, Thomas
    Kowalyszyn, Ruben
    Pazo-Cid, Roberto
    Schenker, Michael
    Feeny, Kynan
    Wang, Rui
    Lei, Ming
    Chen, Clara
    Nathani, Raheel
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2012 - 2020
  • [25] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Additional analysies from 45-month (mo) follow-up of CheckMate 648
    Adenis, A.
    Chau, I.
    Ajani, J. A.
    Kitagawa, Y.
    Xu, J.
    Wyrwicz, L. S.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C-H.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M. I.
    Holtved, E.
    Murphy, M. Blum
    Zhang, J.
    Hu, N.
    Matsumura, Y.
    Kato, K.
    Doki, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S161 - S162
  • [26] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648
    Greil, R.
    Kato, K.
    Ajani, J.
    Doki, Y.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C. -H
    Adenis, A.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M. Ignez
    Holtved, E.
    Murphy, M. Blum
    Patel, A.
    Hu, N.
    Matsumura, Y.
    Chau, I
    Kitagawa, Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 242 - 243
  • [27] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648
    Chau, Ian
    Ajani, Jaffer A.
    Kitagawa, Yuko
    Xu, Jianming
    Wyrwicz, Lucjan S.
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez
    Holtved, Eva
    Murphy, Mariela A. Blum
    Nathani, Raheel
    Hu, Nan
    Matsumura, Yasuhiro
    Kato, Ken
    Doki, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
    Liu, Tianshu
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Ruihua
    Guo, Weijian
    Qin, Shukui
    Yang, Nong
    Lu, Jianwei
    Shitara, Kohei
    Lei, Ming
    Li, Mingshun
    Bao, Nicole
    Chen, Tian
    Shen, Lin
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (04) : 749 - 760
  • [29] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.
    Kato, Ken
    Ajani, Jaffer A.
    Doki, Yuichiro
    Xu, Jianming
    Wyrwicz, Lucjan
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez Freitas Melro
    Holtved, Eva
    Murphy, Mariela A. Blum
    Patel, Apurva
    Hu, Nan
    Matsumura, Yasuhiro
    Chau, Ian
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 290 - 290
  • [30] A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC)
    Sugarman, Ryan
    Botteman, Marc
    Rusibamayila, Nifasha
    Nguyen, Hiep
    Lin, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345